Evidence map›Paper›PMID 35262095›Full record

ArticlemedRxiv : the preprint server for health sciences2022

The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.

Amy B Karger, James D Brien, Jayne M Christen, Santosh Dhakal, Troy J Kemp, Sabra L Klein, Ligia A Pinto, Lakshmanane Premkumar, John D Roback, Raquel A Binder and 49 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

59 authors.

Amy B KargerDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
James D BrienDepartment of Molecular Microbiology & Immunology, Saint Louis University, Saint Louis, Missouri.
Jayne M ChristenFrederick National Laboratory for Cancer Research, Frederick, Maryland.
Santosh DhakalW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Troy J KempFrederick National Laboratory for Cancer Research, Frederick, Maryland.
Sabra L KleinW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Ligia A PintoFrederick National Laboratory for Cancer Research, Frederick, Maryland.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC.
John D RobackDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
Raquel A BinderDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts.
Karl W BoehmeDepartment of Microbiology & Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Suresh BoppanaDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama.
Carlos Cordon-CardoDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
James M CrawfordDepartment of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
John L DaissMicroB-plex, Inc., Atlanta, Georgia.
Alan P DupuisWadsworth Center, New York State Department of Health, Albany, New York.
Ana M EspinoDepartment of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico.
Adolfo Firpo-BetancourtDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
Catherine ForconiDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts.
J Craig ForrestDepartment of Microbiology & Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Roxie C GirardinWadsworth Center, New York State Department of Health, Albany, New York.
Douglas A GrangerSalimetrics, LLC, Carlsbad, California.
Steve W GrangerSalimetrics, LLC, Carlsbad, California.
Natalie S HaddadDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University, Atlanta, Georgia.
Christopher D HeaneyDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Danielle T HuntWadsworth Center, New York State Department of Health, Albany, New York.
Joshua L KennedyDepartments of Pediatrics and Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Christopher L KingDepartment of Pathology, Case Western Reserve School of Medicine, Cleveland, Ohio.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
Kate KruczynskiDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Joshua LaBaerVirginia G Piper Center for Personalized Diagnostics, Arizona State University Biodesign Institute, Tempe, Arizona.
F Eun-Hyung LeeDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University, Atlanta, Georgia.
William T LeeWadsworth Center, New York State Department of Health, Albany, New York.
Shan-Lu LiuCenter for Retrovirus Research, Department of Veterinary Biosciences, Department of Microbial Infection and Immunity, Viruses and Emerging Pathogens Program, Infectious Disease Institute, The Ohio State University, Columbus, Ohio.
Gerard LozanskiDepartment of Pathology, The Ohio State University Medical Center, Columbus, Ohio.
Todd LucasDivision of Public Health and Department of Epidemiology, College of Human Medicine, Michigan State University, East Lansing, Michigan.
Damodara Rao MenduDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
Ann M MoormannDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts.
Vel MuruganVirginia G Piper Center for Personalized Diagnostics, Arizona State University Biodesign Institute, Tempe, Arizona.
Nkemakonam C OkoyeDepartment of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
Petraleigh PantojaUnit of Comparative Medicine, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico.
Anne F PayneWadsworth Center, New York State Department of Health, Albany, New York.
Jin ParkVirginia G Piper Center for Personalized Diagnostics, Arizona State University Biodesign Institute, Tempe, Arizona.
Swetha PinnintiDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama.
Amelia K PintoDepartment of Molecular Microbiology & Immunology, Saint Louis University, Saint Louis, Missouri.
Nora PisanicDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Ji QiuVirginia G Piper Center for Personalized Diagnostics, Arizona State University Biodesign Institute, Tempe, Arizona.
Carlos A SariolUnit of Comparative Medicine, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico.
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
Lusheng SongVirginia G Piper Center for Personalized Diagnostics, Arizona State University Biodesign Institute, Tempe, Arizona.
Tara L SteffenDepartment of Molecular Microbiology & Immunology, Saint Louis University, Saint Louis, Missouri.
E Taylor StoneDepartment of Molecular Microbiology & Immunology, Saint Louis University, Saint Louis, Missouri.
Linda M StyerWadsworth Center, New York State Department of Health, Albany, New York.
Mehul S SutharCenter for Childhood Infections and Vaccines of Children's Healthcare Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, Georgia.
Stefani N ThomasDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Bharat ThyagarajanDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Ania WajnbergDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Jennifer L YatesWadsworth Center, New York State Department of Health, Albany, New York.
Kimia SobhaniDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Role of B Cells in Synovial Inflammation & LN Remodeling in RA ArthritisP01AI078907 · NIAID · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2010 to 2014
$10.8M
Virology Resource CoreU54CA260492 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, SABRA L. · 2020 to 2024
$10.4M
Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4M
Project-004U54CA260563 · NCI · EMORY UNIVERSITY · PI DHODAPKAR, MADHAV V, SANZ, IGNACIO E. · 2020 to 2024
$10.2M
Project 3: Serological Interactions with the Mucosal Innate Immune System Regulates COVID-19 Associated Tissue Damage.U54CA260543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLFGANG, MATTHEW C · 2020 to 2024
$9.8M
Diversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2U54CA260591 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., KARIN, MICHAEL · 2020 to 2024
$9.1M
Project-002U01CA260462 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOPPANA, SURESH B, BRITT, WILLIAM JARVIS · 2020 to 2023
$4.0M
SARS-CoV-2 correlates of protection in a Latino-origin populationU01CA260541 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI BRIEN, JAMES D, LOPEZ, MARCOS · 2020 to 2024
$3.4M
Early Drivers of Humoral Immunity to SARS-CoV-2 InfectionsU01CA260539 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KING, CHRISTOPHER L · 2020 to 2024
$3.4M
Supplement to U01CA260469U01CA260469 · NCI · MICHIGAN STATE UNIVERSITY · PI LUCAS, TODD WILLIAM · 2020 to 2024
$3.2M
High-Throughput Dried Blood Spot (HT-DBS) Technologies in SARS COV-2 Serology and VaccinologyU01CA260508 · NCI · WADSWORTH CENTER · PI MANTIS, NICHOLAS J. · 2020 to 2023
$2.6M
NCI NIH HHS 75N91019D00024NCI NIH HHS U01 CA260462NCI NIH HHS U01 CA260469NCI NIH HHS U01 CA260508NCI NIH HHS U01 CA260526NCI NIH HHS U01 CA260539NCI NIH HHS U01 CA260541NCI NIH HHS U01 CA261276NCI NIH HHS U54 CA260492NCI NIH HHS U54 CA260543NCI NIH HHS U54 CA260563NCI NIH HHS U54 CA260582NCI NIH HHS U54 CA260591NIAID NIH HHS P01 AI078907
6 · The paper itself

Abstract

Background: In October 2020, the National Cancer Institute (NCI) Serological Sciences Network (SeroNet) was established to study the immune response to COVID-19, and "to develop, validate, improve, and implement serological testing and associated technologies." SeroNet is comprised of 25 participating research institutions partnering with the Frederick National Laboratory for Cancer Research (FNLCR) and the SeroNet Coordinating Center. Since its inception, SeroNet has supported collaborative development and sharing of COVID-19 serological assay procedures and has set forth plans for assay harmonization. Methods: To facilitate collaboration and procedure sharing, a detailed survey was sent to collate comprehensive assay details and performance metrics on COVID-19 serological assays within SeroNet. In addition, FNLCR established a protocol to calibrate SeroNet serological assays to reference standards, such as the U.S. SARS-CoV-2 serology standard reference material and First WHO International Standard (IS) for anti-SARS-CoV-2 immunoglobulin (20/136), to facilitate harmonization of assay reporting units and cross-comparison of study data. Results: SeroNet institutions reported development of a total of 27 ELISA methods, 13 multiplex assays, 9 neutralization assays, and use of 12 different commercial serological methods. FNLCR developed a standardized protocol for SeroNet institutions to calibrate these diverse serological assays to reference standards. Conclusions: SeroNet institutions have established a diverse array of COVID-19 serological assays to study the immune response to SARS-CoV-2 virus and vaccines. Calibration of SeroNet serological assays to harmonize results reporting will facilitate future pooled data analyses and study cross-comparisons.

Identifiers

PMID35262095
PMCPMC8902887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.